Recruiting
Phase 3

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

Sponsor:

AstraZeneca

Code:

NCT05583227

Conditions

Eosinophilic Esophagitis

Eligibility Criteria

Sex: All

Age: 12 - 70+

Healthy Volunteers: Not accepted

Interventions

Tezepelumab

Tezepelumab

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information